Literature DB >> 32212295

Understanding the results of the PARAGON-HF trial.

Roberto Ferrari1,2, Alessandro Fucili1, Claudio Rapezzi1,2.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32212295     DOI： 10.1002/ejhf.1797

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN： 1388-9842            Impact factor:   15.534


× No keyword cloud information.
  2 in total

1.  Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.

Authors:  Burkert Pieske; Rolf Wachter; Sanjiv J Shah; Abigail Baldridge; Peter Szeczoedy; Ghionul Ibram; Victor Shi; Ziqiang Zhao; Martin R Cowie
Journal:  JAMA       Date:  2021-11-16       Impact factor: 56.272

2.  Impact of Myocardial Energy Expenditure and Diastolic Dysfunction on One Year Outcome Patients With HFpEF.

Authors:  Yu Wang; Yalan Cao; Shuting Xiang; Shunji Liang; Xiumei Yang; Ning Zhu; Weiyi Fang; Qin Yu
Journal:  Front Physiol       Date:  2022-04-04       Impact factor: 4.755
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.